BioSpace News Archive

Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 1, 2024.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.

The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis is the most common form of precancer, with over 40 million Americans a year developing this condition.

RaySearch Laboratories AB is pleased to announce that Raigmore Hospital in Inverness, Scotland has placed an order for the oncology information system RayCare®.

Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported publication of new preclinical data in the highly reputable scientific journal Cell Reports on the clinical stage antibody CAN10, specifying the precise interactions between CAN10 and its target IL1RAP and highlighting its functional capabilities to block multiple signaling pathways.

Berlin, 8th of April, 2024 - Konstantinos Mouratis, CEO of Therapyte, spoke at the European RWD Summit held by Honic at the GovTech Campus in Berlin, Germany.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its first quarter 2024 financial results on Tuesday, April 30, 2024.

NANOBIOTIX announced that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023, on Wednesday, April 24, 2024, after the close of the US market.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients.

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.